<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742805</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002729</org_study_id>
    <nct_id>NCT02742805</nct_id>
  </id_info>
  <brief_title>Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation</brief_title>
  <official_title>Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selina Gierer, D.O.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research is intended to determine if supplementation of relatively high dose
      vitamin D in chronic urticaria patients receiving omalizumab will result in continued
      symptomatic control of hives after the discontinuation of omalizumab.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total Urticaria Severity Score (USS)</measure>
    <time_frame>Change from Baseline to Month 6</time_frame>
    <description>The USS is a questionnaire which is used to measure urticaria severity. The questionnaire is comprised on 9 questions with each question having 7 total responses on a likert-type scale. Responses to each question range from 0 to 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects restarted on Omalizumab</measure>
    <time_frame>8 Months</time_frame>
    <description>Number of participants restarted on Omalizumab after coming off it at Month 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total Urticaria Severity Score (USS)</measure>
    <time_frame>Change from Baseline to Month 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (4,000 IU/day)</intervention_name>
    <description>High Dose of 4,000 IU/day.</description>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (400 IU/day)</intervention_name>
    <description>Low Dose of 400 IU/day.</description>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Standard of care dose.</description>
    <arm_group_label>High Dose Vitamin D</arm_group_label>
    <arm_group_label>Low Dose Vitamin D</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician diagnosed chronic urticaria

          -  Currently be receiving omalizumab therapy for the treatment of chronic idiopathic
             urticaria and be well controlled with a USS &lt;25

        Exclusion Criteria:

          -  Not capable of informed consent.

          -  Not capable of answering the questionnaire.

          -  Subjects with a pure physical urticaria.

          -  Pregnant or lactating women.

          -  Subjects with hypercalcemia (calcium &gt; 10.3 mg/dl) or renal insufficiency (GFR &lt;50
             ml/min).

          -  Subjects with prior anaphylaxis to omalizumab.

          -  Currently taking high dose vitamin D supplementation.

          -  Prior high dose vitamin D supplementation for urticaria with failure.

          -  Baseline 25(OH)D &gt;80 ng/ml

          -  Subjects with sarcoidosis, hyperparathyroidism, histoplasmosis, lymphoma or
             tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selina Gierer, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Selina Gierer, D.O.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>hives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

